Osmotica Pharmaceutical Corp and Upstate Pharma, LLC, a subsidiary of UCB, Inc., Announce the Availability of Venlafaxine Extended-Release Tablets

Osmotica Pharmaceutical Corp. is announcing that Venlafaxine Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, which was approved by the U.S. Food and Drug Administration in May, is now commercially available through its marketing partner, Upstate Pharma, LLC, a subsidiary of UCB, Inc. Shipments of the product to wholesalers and other commercial outlets began September 30, 2008 and promotion of the product will commence later in the month. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, “We are excited about the launch of this innovative product and look forward to a successful commercial relationship.”

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

WILMINGTON, N.C. (PRWEB) October 9, 2008

Important Safety Information

There is an increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. Venlafaxine HCl Extended Release Tablets are not approved for use in pediatric patients.

People taking Monoamine oxidase inhibitors (MAOIs) should not take Venlafaxine HCl Extended-release Tablets. Venlafaxine HCl Extended-release Tablets may raise blood pressure in some patients. Your blood pressure should be controlled before starting treatment and should be monitored regularly. Other side effects reported in at least 10% of patients in clinical studies and at a rate at least twice that of the placebo group include: abnormal ejaculation (men), anorexia, dizziness, dry mouth, impotence, insomnia, nausea, nervousness, somnolence, sweating, and weakness. Ask your doctor if Venlafaxine HCl Extended-release Tablets are right for you.

About Osmotica Pharmaceutical

Osmotica Pharmaceutical is part of a multi-national group of pharmaceutical companies (the "Osmotica Group") specializing in neurology based drug therapies and delivery technologies. The Osmotica Group has a portfolio of products in various stages of development focused in the treatment of Parkinson's disease. In addition, the Osmotica Group utilizes its well established drug delivery technologies (including its Osmodex® technologies) and its expertise to develop drug candidates for partner companies. The Osmotica Group has a track record of successfully developing and commercializing products in the US, Europe and other countries around the world.

The Osmotica Group's principal operations are located in the United States and Argentina and its products are manufactured in the U.S., Argentina and Spain.

For more information on the Company, please visit Osmotica's website at http://www.osmotica.com. This press release is directed to residents of the United States.

Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
PDF Version PDF Printer Friendly VersionPrint

Contact

Please visit our website